Vincerx stalls again
The group reports responses with its CD123-targeting ADC, but cash is running short.
AACR 2024 – Vincerx overreaches
The company's comparison of its ADCs to Enhertu seems farfetched.
Early tests approach for Vincerx’s conjugate revolution
The company reckons its tech could solve problems with current ADCs, but the market isn’t giving it much credit yet.
